Alliances
The collaboration will focus on Inovio’s VGX-3100, which stimulates a specific immune response to HPV-16 and HPV-18, targeting the infection and causing destruction of precancerous cells.
Financial terms of the deal were not disclosed, but Genentech aims to use Parvus’ technology to target IBD and Celiac.
Ginkgo Bioworks bought Warp Drive Bio’s genome mining platform, which includes its genome mining team, technology and database.
Third CodeEvolver® licensing agreement with a major pharma company
The move by Vertex is part of the company’s plan to diversify its drug discovery strategies.
Today, Civica Rx announced it had inked a product supply agreement with Xellia Pharmaceuticals, where Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civica’s members.
Teijin Limited announced today that it has signed a research and development agreement with the Japan Agency for Medical Research and Development (AMED) to form an industry-government-academia partnership that will explore preventive and therapeutic drugs for frail elderly people as designated under AMED’s Cyclic Innovation for Clinical Empowerment program(CiCLE) in October 2018.
Eisai Co., Ltd. announced today that it has entered into a license agreement with medac Gesellschaft fur klinische Spezialpraparate mbH for the commercialization of its anti-rheumatic agent methotrexate (MTX) subcutaneous injection (pre-filled syringe) in Japan.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
The triple combination therapy does not use a chemotherapy agent in its experimental treatment for an aggressive blood cancer.
PRESS RELEASES